Save over 80% on Lilly Verzenio - known as Ramiven internationally. Both Verzenio and Ramiven are manufactured at the same factory:
Manufacturer:
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain
Information about Ramiven (Abemaciclib)
Ramiven, containing the active ingredient abemaciclib, is an oral medication used to treat specific types of breast cancer. Abemaciclib is a CDK4/6 inhibitor, meaning it blocks the activity of cyclin-dependent kinases 4 and 6, which are proteins involved in the regulation of the cell cycle. By inhibiting these kinases, Ramiven prevents cancer cells from dividing and growing, thus helping to slow down or stop the progression of cancer.
Product Highlights
- Ramiven is primarily used in combination with endocrine therapy (such as letrozole or an aromatase inhibitor) for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer.
- Ramiven is used as an adjuvant therapy for early-stage, hormone receptor-positive, HER2-negative breast cancer, particularly for patients at high risk of recurrence, following surgery, or chemotherapy.
- Ramiven is frequently prescribed in combination with other drugs such as letrozole, fulvestrant, or anastrozole to improve outcomes in advanced or metastatic cases of breast cancer.
Key Ingredient
Key Benefits
- Ramiven is specifically designed for cancers that express estrogen or progesterone receptors, making it effective for a significant portion of breast cancer cases.
- By inhibiting CDK4 and CDK6, Ramiven helps reduce the ability of cancer cells to divide and proliferate.
- Clinical studies have shown that Ramiven, especially when used in combination with endocrine therapies, can improve progression-free survival in both metastatic and early-stage breast cancer.
- As an oral medication, Ramiven offers a convenient option for patients, reducing the need for intravenous treatment.
- When used in combination with other targeted or hormonal therapies, abemaciclib has shown improved efficacy in managing breast cancer.
Direction of Use
- Oral tablets.
- The recommended dose of Ramiven is 150 mg twice daily, although this may vary based on the patient's condition and how they tolerate the medication.
- Tablets should be taken with or without food, ideally at the same time each day, to maintain consistent blood levels.
- The dose may be reduced in the event of significant side effects, particularly neutropenia (low white blood cell count) or diarrhea.
- Patients should be monitored regularly for side effects, including blood cell counts and liver function.
Safety Concerns
- Common side effects
- Diarrhea (one of the most frequent side effects)
- Fatigue and general weakness
- Nausea and vomiting
- Decreased appetite
- Increased liver enzymes (indicating potential liver problems)
Serious side effects
- A decreased white blood cell count, which increases the risk of infections.
- Increased liver enzymes or jaundice may signal liver damage.
- Increased risk of blood clots.
- If not managed properly, can lead to dehydration and other complications.
Drug interactions
- Drugs that affect liver enzymes (such as certain antifungal or antiviral medications) can alter abemaciclib levels.
- When combined with other cancer treatments, there may be a higher risk of neutropenia or other side effects.
Avoid Ramiven (Abemaciclib) If
- Patients who are allergic to abemaciclib or any of its components should avoid taking Ramiven.
- Ramiven should be avoided in patients with severe liver dysfunction or active liver disease, as it can worsen liver function.
- Ramiven is contraindicated during pregnancy as it may harm a developing fetus. Women of childbearing age should use effective contraception while taking this medication.
- It is not recommended for use in breastfeeding women, as the drug may pass into breast milk and harm the infant.
- If a patient has a significantly low white blood cell count (neutropenia), Ramiven should be avoided until blood counts are improved.
